Laboratorios Farmaceuticos Rovi (XMAD:ROVI) 3-Year EBITDA Growth Rate : 40.10% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi 3-Year EBITDA Growth Rate?

Laboratorios Farmaceuticos Rovi's EBITDA per Share for the three months ended in Dec. 2023 was €1.41.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average EBITDA Per Share Growth Rate was -12.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 40.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 57.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 25.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Laboratorios Farmaceuticos Rovi was 123.30% per year. The lowest was -6.30% per year. And the median was 10.90% per year.

Competitive Comparison of Laboratorios Farmaceuticos Rovi's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorios Farmaceuticos Rovi's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 3-Year EBITDA Growth Rate falls into.

Laboratorios Farmaceuticos Rovi 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Laboratorios Farmaceuticos Rovi 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.